Mersana Therapeutics GAAP EPS of -$4.87 misses by $0.80, revenue of $3.06M misses by $3M

* Mersana Therapeutics press release [https://seekingalpha.com/pr/20199128-mersana-therapeutics-provides-business-update-and-announces-second-quarter-2025-financial] (NASDAQ:MRSN [https://seekingalpha.com/symbol/MRSN]): Q2 GAAP EPS of -$4.87 misses by $0.80.
* Revenue of $3.06M (+33.0% Y/Y) misses by $3M.
* Net cash used in operating activities for the second quarter of 2025 was $22.6 million, which included $2.4 million in severance-related payments.
* Cash and cash equivalents as of June 30, 2025 were $77.0 million.

MORE ON MERSANA THERAPEUTICS

* Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript [https://seekingalpha.com/article/4787121-mersana-therapeutics-inc-mrsn-q1-2025-earnings-call-transcript]
* Mersana Therapeutics Q2 2025 Earnings Preview [https://seekingalpha.com/news/4484060-mersana-therapeutics-q2-2025-earnings-preview]
* Mersana Therapeutics to execute 1-for-25 reverse stock split [https://seekingalpha.com/news/4471420-mersana-therapeutics-to-execute-1-for-25-reverse-stock-split]
* Seeking Alpha’s Quant Rating on Mersana Therapeutics [https://seekingalpha.com/symbol/MRSN/ratings/quant-ratings]
* Historical earnings data for Mersana Therapeutics [https://seekingalpha.com/symbol/MRSN/earnings]